Clinical trials: sponsored by H. Lundbeck A/S
Depression, Major Depressive Disorder
Memory Functioning and Antidepressant Treatment
Major Depressive Disorder (MDD) is a serious illness associated with considerable morbidity, risk of suicide and adverse social consequences (Montgomery et al., 1994a).
- Trial name
- NCT00296933
- Testing
- Escitalopram, Bupropion XL
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- University Health Network, Toronto
Healthy
Specific Effects of Escitalopram on Neuroendocrine Response
Citalopram, a selective serotonin reuptake inhibitor (SSRI), is used as a neuroendocrine probe in human subjects to assess serotonin (5-hydroxytryptamine; 5-HT) function as reflected in prolactin and plasma cortisol release.
- Trial name
- NCT00150527
- Testing
- Citalopram, Escitalopram, Dexamethasone
- Where
- Canada
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Queen's University
Depression
DECARD: Study of Escitalopram in the Prevention of Depression in Patients With Acute Coronary Syndrome
Objective: To evaluate the efficacy of preventive treatment with a selective serotonin reuptake inhibitor (SSRI) (escitalopram) in the first year after acute coronary syndromes (ACS).
- Trial name
- NCT00140257
- Testing
- Escitalopram
- Where
- Denmark
- Volunteers
- 240 people
- Sponsor
- Bispebjerg Hospital
Healthy
The Effect of Escitalopram on the Pharmacokinetics and Pharmacodynamics of Tramadol in Healthy Subjects
Escitalopram will be given to a panel of 16 healthy subject for 9 days. On the ninth day a single dose of tramadol is administered to the subjects and pharmacokinetic(PK) and pharmacodynamic(PD) measurements are done for the next…
- Trial name
- NCT00692263
- Testing
- escitalopram and tramadol
- Where
- Denmark
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University of Southern Denmark
Obsessive Compulsive Disorder
Treatment Youth With Obsessive-Compulsive Disorder
Although research suggests that patients with obsessive-compulsive disorder (OCD) exhibit specific deficits in their high cognitive processes, it is still unknown how these deficits relate to the clinical symptoms of the…
- Trial name
- NCT00708240
- Testing
- Escitalopram
- Where
- Canada
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Ottawa
Schizophrenia
Compare the Effects of Bifeprunox and Quetiapine on Weight Changes in Stable Schizophrenic Patients
The primary objective of the study is to evaluate changes in weight short and long term with bifeprunox and quetiapine. Study participation for the subject is 57 weeks.
- Trial name
- NCT00396214
- Testing
- Bifeprunox, Quetiapine
- Where
- 151 sites in United States, Argentina and 12 more
- Volunteers
- 83 people
- Sponsor
- Solvay Pharmaceuticals
Schizophrenia and Schizoaffective Disorder
Switch Study of Existing Atypical Antipsychotics to Bifeprunox
The study will evaluate the safety and tolerability of switching subjects with schizophrenia or schizoaffective disorder from their existing antipsychotic medication to Bifeprunox.
- Trial name
- NCT00347425
- Testing
- Aripiprazole, Olanzapine, Risperidone
- Where
- 122 sites in United States, Argentina and 7 more
- Volunteers
- 286 people
- Sponsor
- Solvay Pharmaceuticals
Parkinson Disease
A Longitudinal Observational Follow-up of the PRECEPT Study Cohort
The purpose of this study is to longitudinally follow consenting clinical trial participants who participated in PRECEPT (A Randomized, Double Blind, Placebo Controlled, Dose Finding Study to Assess the Efficacy and Safety of CEP…
- Trial name
- PostCEPT (NCT00605163)
- Where
- 55 sites in United States, Canada
- Volunteers
- 530 people
- Sponsor
- The Parkinson Study Group
Aphasia, Stroke
Memantine and Intensive Speech-Language Therapy in Aphasia
Aphasia, the loss or impairment of language caused by brain damage, is one of the most devastating cognitive impairments of stroke. Aphasia can be treated with combination of speech-language therapy and drugs.
- Trial name
- NCT00640198
- Testing
- memantine, constraint-induced language therapy (CIAT)
- Where
- Spain
- Volunteers
- 28 people
- Sponsor
- Gabinete Berthier y Martínez
Atrial Fibrillation
Cavotricuspid Isthmusblock and Circumferential Pulmonary Vein Isolation in Patients With Atrial Fibrillation
Atrial fibrillation (AF) is the most common cardiac arrhythmia. Pulmonary vein isolation (PVI) in the left atrium using radiofrequency energy is a new and promising non-medical treatment in patients with symptomatic AF with…
- Trial name
- NCT00247780
- Testing
- Pulmonary vein isolation and cavotricuspid ishtmusblock
- Where
- Denmark
- Volunteers
- 149 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Healthy
Pupillary Changes as a Potential Biomarker for Escitalopram in Relation to CYP2C19 Polymorphism
To study the impact of CYP2C19 polymorphism on escitalopram pharmacokinetics and pharmacodynamics measured as changes in pupil diameter
- Trial name
- NCT00397059
- Testing
- Escitalopram
- Where
- Denmark
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- University of Southern Denmark
Pain, Polyneuropathies
Escitalopram as a Treatment for Pain in Polyneuropathy
Many people with polyneuropathy suffer from pain which is difficult to treat. Escitalopram is a relatively new drug used in the treatment of depression.
- Trial name
- NCT00162968
- Testing
- escitalopram
- Where
- 2 sites in Denmark
- Volunteers
- 50 people
- Sponsor
- Odense University Hospital
Primary Insomnia
A Prospective Open-Label Extension Study of Gaboxadol in Primary Insomnia
To evaluate the safety and tolerability of gaboxadol in primary insomnia
- Trial name
- NCT00209950
- Testing
- Gaboxadol
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- H. Lundbeck A/S
Primary Insomnia
A Study of Gaboxadol in Primary Insomnia
To evaluate the efficacy safety and tolerability of gaboxadol in primary insomnia.
- Trial name
- NCT00209924
- Testing
- Gaboxadol
- Where
- Sweden
- Volunteers
- 505 people
- Sponsor
- H. Lundbeck A/S
Primary Insomnia
A Study of Gaboxadol in Primary Insomnia
To evaluate the safety and tolerability of gaboxadol in primary insomnia.
- Trial name
- NCT00209963
- Testing
- Gaboxadol
- Volunteers
- 600 people
- Sponsor
- H. Lundbeck A/S
Primary Insomnia
A Study of Gaboxadol in Primary Insomnia
To evaluate the safety and tolerability of gaboxadol in primary insomnia.
- Trial name
- NCT00209846
- Testing
- Gaboxadol
- Where
- Sweden
- Volunteers
- 320 people
- Sponsor
- H. Lundbeck A/S
Primary Insomnia
A Prospective Active-Reference Study of Gaboxadol in Primary Insomnia
To evaluate the efficacy safety and tolerability of gaboxadol in primary insomnia
- Trial name
- NCT00209937
- Testing
- Gaboxadol
- Volunteers
- 675 people
- Sponsor
- H. Lundbeck A/S
Depressive Syndrome
Study of Escitalopram Versus Placebo in the Treatment of Depressive Syndrome in Alzheimer's Disease, Vascular Dementia, and Mixed Vascular and Alzheimer's Dementia
The goal of the present study is to compare the effectiveness of the active (S)-enantiomer of citalopram, escitalopram with placebo in the treatment of patients with depressive syndrome complicating Alzheimer's dementia (AD)…
- Trial name
- NCT00229333
- Testing
- Escitalopram
- Where
- Israel
- Volunteers
- 40 people
- Sponsor
- Sheba Medical Center
Charcot Joint, Diabetic Foot
Characterizing and Diagnosis's of the Charcot Foot (Charcot Osteoarthropathy) in Diabetic Patients
The condition Charcot foot has been known in more than 130 years, and yet there still remains a large effort to find the cause, diagnostic and medical treatment of the condition.
- Trial name
- NCT00157222
- Where
- Denmark
- Volunteers
- 50 people
- Sponsor
- Bispebjerg Hospital
Aphasia, Stroke
Memantine and Constraint-Induced Language Therapy in Chronic Poststroke Aphasia:A Randomized Controlled Trial
Aphasia, the loss or impairment of language caused by brain damage, is one of the most devastating cognitive impairments of stroke. Aphasia can be treated with combination of speech-language therapy and drugs.
- Trial name
- NCT00196703
- Testing
- memantine, constraint-induced language therapy
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Gabinete Berthier y Martínez